Sutro Biopharma (STRO) Projected to Release Quarterly Earnings on Thursday

Sutro Biopharma (NASDAQ:STRO) is projected to announce its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Sutro Biopharma to post earnings of ($1.6407) per share and revenue of $14.11 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 13, 2026 at 9:30 AM ET.

Sutro Biopharma (NASDAQ:STRO) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($2.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.19) by ($0.14). The firm had revenue of $9.84 million during the quarter, compared to the consensus estimate of $11.96 million. On average, analysts expect Sutro Biopharma to post ($8.12) EPS for the current fiscal year and ($6.95) EPS for the next fiscal year.

Sutro Biopharma Stock Performance

Shares of STRO opened at $9.51 on Wednesday. The firm has a market capitalization of $157.68 million, a price-to-earnings ratio of -0.79 and a beta of 1.56. Sutro Biopharma has a one year low of $7.15 and a one year high of $43.85. The stock’s fifty day moving average is $14.93 and its 200-day moving average is $22.75.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on STRO shares. HC Wainwright reiterated a “buy” rating on shares of Sutro Biopharma in a research report on Friday, October 16th. Weiss Ratings downgraded shares of Sutro Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, October 19th. Wedbush restated an “outperform” rating and set a $60.00 price target on shares of Sutro Biopharma in a research report on Thursday, October 15th. Wall Street Zen raised shares of Sutro Biopharma from a “strong sell” rating to a “sell” rating in a research note on Saturday. Finally, Wells Fargo & Company started coverage on shares of Sutro Biopharma in a report on Wednesday, September 30th. They issued an “overweight” rating and a $49.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $49.50.

About Sutro Biopharma

Sutro Biopharma, Inc is a clinical-stage biotechnology company focused on developing medicines for cancer and other serious diseases. The company uses its proprietary XpressCF cell-free protein synthesis platform to design and manufacture targeted biologic therapies, including antibody-drug conjugates (ADCs) and cancer immunotherapies.

Sutro’s research programs have included luveltamab tazevibulin, also known as STRO-002, a folate receptor alpha-targeted ADC being investigated for ovarian and endometrial cancers.